Catalent (CTLT) Shares are Down -0.91%

Catalent (CTLT) : During the past 4 weeks, traders have been relatively bearish on Catalent (CTLT), hence the stock is down -1.91% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -0.26% relative to the S&P 500. The 4-week change in the price of the stock is -2.11% and the stock has fallen -0.91% in the past 1 week.

For the current week, the company shares have a recommendation consensus of Buy. The stock has recorded a twenty day Moving Average of 0.66% and the fifty day Moving Average is 3.61%. Catalent, Inc. has dropped 13.76% during the last three month period . Year-to-Date the stock performance stands at -0.12%.

Catalent (CTLT) : The highest short term price target forecast on Catalent (CTLT) is $31 and the lowest target price is $23. A total of 5 equity analysts are currently covering the company. The average price of all the analysts is $26.5 with a standard deviation of $2.87.


Catalent (NYSE:CTLT): stock turned positive on Friday. Though the stock opened at $24.92, the bulls momentum made the stock top out at $25.17 level for the day. The stock recorded a low of $24.74 and closed the trading day at $25, in the green by 0.12%. The total traded volume for the day was 970,819. The stock had closed at $24.97 in the previous days trading.

Catalent, Inc. is a provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. The Companys segments include Oral Technologies, Medication Delivery Solutions, and Development and Clinical Services. The Oral Technologies segment provides advanced oral delivery technologies, including formulation, development and manufacturing of oral dose forms for prescription and consumer health products across all phases of a molecules lifecycle. The Medication Delivery Solutions segment provides formulation, development and manufacturing services for delivery of drugs and biologics, administered through injection, inhalation and ophthalmic routes, using both traditional and advanced technologies. The Development and Clinical Services segment provides manufacturing, packaging, storage and inventory management for drugs and biologics in clinical trials.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.